SOLV · 10-Q · 2026Q3

Solventum Corp

Filed 2026-11-05 · Healthcare · View original filing on EDGAR

Everything SOLV's SEC filings said, ranked

Ranked Events

• Operating Margin DriversImportance 62 · Surprise 46
  Total operating income was $68 million in the third quarter of 2026, down 96.0% from the prior-year quarter, and $327 million for the first nine months, down 84.0%. The comparison reflects the $1.5 billion gain on the…
• Net Income and ProfitabilityImportance 62 · Surprise 46
  For the three months ended September 30, 2026, diluted earnings per share were a loss of $0.07, compared with earnings of $7.22 in the prior-year quarter. For the nine months ended September 30, 2026, diluted earnings…
• Headcount / RestructuringImportance 52 · Surprise 42
  Solventum approved its four-year global “Transform for the Future” initiative in November 2025 to reshape its cost structure, improve operational efficiency, and reposition for profitable growth. Planned actions…
• Trade Policy and TariffsImportance 49 · Surprise 60
  On February 20, 2026, the U.S. Supreme Court held that the International Emergency Economic Powers Act (IEEPA) does not authorize presidential tariffs; the IEEPA tariffs that had affected Solventum were refunded in…
• Revenue Performance and MixImportance 49 · Surprise 32
  Third-quarter 2026 net sales were $1,949 million, down 7.0% from $2,096 million a year earlier; organic sales decreased 2.8%. Nine-month net sales were $6,165 million, down 2.6% from $6,327 million, while organic sales…
• Liquidity and Cash PositionImportance 45 · Surprise 38
  At September 30, 2026, Solventum held $451 million in cash and cash equivalents, down $427 million, or 48.6%, from $878 million at December 31, 2025. Approximately $365 million of the September balance was held by…
• Operating Expense TrendsImportance 44 · Surprise 40
  SG&A rose to 41.7% of total net sales in the third quarter of 2026 from 37.2% a year earlier, and to 41.6% for the first nine months from 36.7%. The quarterly increase reflected higher costs from the Transform for the…
• Gross Margin DriversImportance 43 · Surprise 32
  Cost of product increased to 53.8% of sales of product in the third quarter of 2026 from 53.1% a year earlier, primarily because of freight, warehousing and other costs supporting the July U.S. ERP deployment. For the…
• Liquidity and Debt PositionImportance 42 · Surprise 14
  At September 30, 2026, long-term debt excluding current portions was $4.561 billion, down from $5.035 billion at December 31, 2025, a decrease of $474 million. Total debt, including other borrowings, was $5.068 billion…
• Litigation and Legal RiskImportance 40 · Surprise 42
  Solventum has agreed to indemnify 3M for uninsured liabilities related to the Bair Hugger patient warming system, manage the litigation, and pay legal expenses. The proceedings include approximately 8,400 U.S.…
• Strategic Business SeparationImportance 40 · Surprise 42
  On August 5, 2026, Solventum announced its intention to pursue a separation of its Health Information Systems business as part of portfolio optimization. The company is evaluating a range of separation pathways, with…
• Supply Chain Tariff ImpactImportance 40 · Surprise 42
  Solventum submitted refund requests accepted by U.S. Customs and Border Protection totaling approximately $120 million, including interest, in June 2026. The company recognized a receivable for the full amount and a…
• Geographic Revenue PerformanceImportance 36 · Surprise 14
  For the first nine months of 2026, U.S. net sales were $3,605 million, or 58.5% of worldwide sales, and organic growth was 4.5%; International sales were $2,560 million, or 41.5%, with organic growth of 0.7%. In the…
• Income Tax Rate ChangesImportance 33 · Surprise 38
  Solventum’s effective tax rate for the third quarter of 2026 was negative 6.5%, compared with 16.4% in the third quarter of 2025. The company attributed the decrease primarily to the nonrecurrence of tax expense…
• Market Demand TrendsImportance 32 · Surprise 24
  Third-quarter sales were negatively affected by customer inventory normalization after approximately $125 million of advanced ordering in the second quarter ahead of the July 2026 U.S. ERP deployment. MedSurg organic…
• Geographic Market CommentaryImportance 31 · Surprise 32
  In the third quarter, U.S. organic sales declined 4.2%, with declines in MedSurg and Dental Solutions reflecting the prior-quarter advanced ordering ahead of the ERP deployment; Health Information Systems increased.…
• Segment Revenue PerformanceImportance 30 · Surprise 14
  For the first nine months of 2026, MedSurg sales rose 6.6% to $3,818 million, Dental Solutions sales rose 6.0% to $1,067 million, and Health Information Systems sales rose 4.0% to $1,052 million. In the third quarter,…
• Operating Cash Flow TrendsImportance 20 · Surprise 24
  Cash flows provided by operating activities decreased in the first nine months of 2026 compared with the first nine months of 2025. Solventum attributed the decrease primarily to higher accounts receivable balances,…
• Products and TechnologyImportance 13 · Surprise 6
  MedSurg growth was led by I.V. site management and negative pressure wound therapy products, including Tegaderm CHG within Infection Prevention and Surgical Solutions. The company said its SKU rationalization program…
• Capital Return ProgramImportance 13 · Surprise 6
  Solventum’s board approved a share repurchase program in November 2025 authorizing purchases of up to a stated dollar amount of common stock; the filing text provided does not display that authorization amount. During…

Revenue by Product (in millions)

Revenue by Geography (in millions)